1 / 9

Access to ARVs in low and middle income countries -

Access to ARVs in low and middle income countries -. Joseph Perriëns Coordinator HIV technology and commodities HIV dept. World Health Organization. ARV price transparency. Median price (US$ ppy ) paid for second line treatment regimens by LMICs, 2008-2013.

arnaud
Télécharger la présentation

Access to ARVs in low and middle income countries -

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Access to ARVs in low and middle income countries- Joseph Perriëns Coordinator HIV technology and commodities HIV dept. World Health Organization

  2. ARV price transparency Median price (US$ppy) paid for second line treatment regimens by LMICs, 2008-2013 Average price (US$ppy) paid for first line treatment by LMICs, 2004-2013 Median price (US$ppy) paid for third-line drugs by LMICs, 2008-2013 Source: Global Price Reporting Mechanism http://www.who.int/hiv/amds/gprm/en/

  3. Using price data…Median price and range (US$ ppy) of first line treatment regimens in LMIC, 2013 Source: Global Price Reporting Mechanism http://www.who.int/hiv/amds/gprm/en/

  4. Increasing supply security

  5. Stock-outs require action in financing, supply planning and distribution

  6. Regulatory approvals: a neglected area% of 139 countries with at least 1 registered supplier of: Paediatric formulations Adult formulations In 2012, WHO launched a collaborative procedure with national regulatory authorities to fast-track registration of prequalified medicines. 19 countries now participate.

  7. Progress in intellectual property • Geographic scope of voluntary licenses increased, and new drugs were licensed, e.g.: • TDF: to 112 countries (Gilead via MPP) • ATV: to 110 countries (BMS via MPP) • Dolutegravir: to 144 countries (ViiV via MPP) • RPV: to 112 countries (J&J, bilaterally) • Countries with no access to voluntary licenses negotiated lower prices, and have at times resorted to compulsory licenses • Newer drugs like DRV, RAL, EVG, RPV and TAF remain concerns

  8. Concentration: a threat for competition and supply security Source: Global Price Reporting Mechanism http://www.who.int/hiv/amds/gprm/en/

  9. Acknowledgements People (helped write) Vincent Habiyambere (WHO), Boniface Dongmo-Nguimfack (WHO), Peter Beyer (WHO), Francis Aboageye-Nyame (SIAPS/MSH), Martin Autun (GFATM), Nathan Ford (WHO), Robert Matiru (UNITAID), David Jamieson (SCMS), Laurence Läser (WHO), Martina Penazzato (WHO), Chris Wright (JSI), Dominque Zwinkels (SCMS), G Hirnschall (WHO), Andrew Ball (WHO), Michel Beusenberg (WHO), Esteban Burone (MPP), Cees De Joncheere (WHO), Meg Doherty (WHO), Jane Galbao (UNITAID), Zafar Mirza (WHO), Taufiqur Rahman (UNITAID), Jaqueline Sawyer (WHO), Marco Vitoria (WHO), Gundo Weiler (WHO), colleagues in WIPO and WTO. Organizations (contributed data) CHAI, CPS/WHO, GFATM, IDA, JSI, MissionPharma, UNICEF, SCMS, SIAPS/MSH, UNAIDS ,UNITAID, USAID. Companies (contributed data) Abbvie,Anhui Biochem United Pharm. Co., APIChem Chemical Technology Co. Arch Pharmalabs, Aurobindo Pharma, Aspen Pharmacare, Boehringer Ingelheim, Bristol-Myers-Squibb, CIPLA, Emcure Pharmaceuticals, Gilead Sciences, Glaxo-Smith-Kline, Hoffmann La Roche, Hetero, J&J, Lonzeal Pharmaceuticals, McLeod, Merck Sharp & Dohme, Microlabs, Mylan, Ranbaxy, Shandong Xinhua Pharm. Co., Shanghai Desano Chem. Pharm. Co, Strides Arcolab, Varichem, ViiV.

More Related